BFPET for Regional Myocardial Perfusion Imaging

Exclusion Criteria

• •Any clinically significant acute or unstable physical or psychological disease judged by the investigators based on medical history or screening physical examination;
• •Blood pressure over 180/100mmHg
• •Acute changes in comparison to most recent ECG;
• •Recent (within 3 months) cardiac arrest, unstable angina, cerebro-vascular accident (CVA), CABG or PCI
• •Any pacemaker or defibrillator implanted within the last three months;
• •Inability to remain in camera for approximately 60 minutes
• •Bronchospasm
• •Serum creatinine \> 2 mg/dL;
• •Cancer patients who have received chemotherapy or radiation therapy within the past 60 days.
• •Any exposure to any investigational drug(s) or medical device(s) within four (4) weeks prior to imaging study;
• •Any physical or psychological disease judged by the investigators to be incompatible with the study, based on medical history or screening physical examination.
• •NYHA Class III or IV Congestive heart failure;
• •Subject has symptomatic hypotension
• •Allergic or intolerant to aminophylline, nitroglycerin or metoprolol
• •Allergic or intolerant to regadenoson or any of its excipients
• •Prior participants in the study.
• •Female subjects only: Positive serum and/or urine pregnancy test or is lactating or the possibility of pregnancy cannot be ruled out prior to dosing.
• •Females not of child-bearing potential require confirmatory documentation in their medical records or must have a negative pregnancy test within 4 hours prior to receiving the test drug and agree to use an acceptable form of birth control for at least 30 days following BFPET administration.